Altimmune’s (ALT) “Buy” Rating Reaffirmed at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Altimmune (NASDAQ:ALT) in a research report sent to investors on Tuesday morning,Benzinga reports. HC Wainwright currently has a $12.00 target price on the stock.

Other research analysts have also issued research reports about the company. Stifel Nicolaus started coverage on Altimmune in a report on Wednesday, January 8th. They issued a “buy” rating and a $18.00 price objective on the stock. William Blair restated a “market perform” rating on shares of Altimmune in a report on Friday, March 14th. Two research analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $20.83.

Altimmune Price Performance

Shares of NASDAQ:ALT opened at $5.78 on Tuesday. Altimmune has a 1 year low of $5.14 and a 1 year high of $11.16. The firm has a market capitalization of $445.14 million, a price-to-earnings ratio of -3.73 and a beta of 0.87. The business’s 50 day moving average price is $6.35 and its 200-day moving average price is $7.09.

Altimmune (NASDAQ:ALT) last announced its quarterly earnings data on Thursday, February 27th. The company reported ($0.33) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.34) by $0.01. The company had revenue of $0.01 million for the quarter, compared to analyst estimates of $0.00 million. Altimmune had a negative return on equity of 55.81% and a negative net margin of 199,076.92%. On average, sell-side analysts expect that Altimmune will post -1.35 earnings per share for the current year.

Insider Buying and Selling

In other Altimmune news, CFO Gregory L. Weaver acquired 10,000 shares of the business’s stock in a transaction that occurred on Thursday, March 13th. The stock was purchased at an average cost of $5.20 per share, with a total value of $52,000.00. Following the transaction, the chief financial officer now owns 10,000 shares of the company’s stock, valued at $52,000. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Corporate insiders own 4.10% of the company’s stock.

Institutional Trading of Altimmune

Hedge funds and other institutional investors have recently modified their holdings of the business. Barclays PLC grew its position in Altimmune by 1.1% in the 4th quarter. Barclays PLC now owns 157,528 shares of the company’s stock valued at $1,135,000 after acquiring an additional 1,787 shares in the last quarter. Rafferty Asset Management LLC increased its stake in Altimmune by 1.3% during the fourth quarter. Rafferty Asset Management LLC now owns 157,750 shares of the company’s stock worth $1,137,000 after purchasing an additional 1,964 shares during the period. JPMorgan Chase & Co. increased its stake in Altimmune by 2.0% during the fourth quarter. JPMorgan Chase & Co. now owns 102,940 shares of the company’s stock worth $742,000 after purchasing an additional 2,028 shares during the period. B. Riley Wealth Advisors Inc. increased its stake in Altimmune by 12.9% during the third quarter. B. Riley Wealth Advisors Inc. now owns 23,454 shares of the company’s stock worth $144,000 after purchasing an additional 2,687 shares during the period. Finally, MetLife Investment Management LLC increased its stake in Altimmune by 7.0% during the fourth quarter. MetLife Investment Management LLC now owns 44,474 shares of the company’s stock worth $321,000 after purchasing an additional 2,897 shares during the period. 78.05% of the stock is owned by institutional investors and hedge funds.

About Altimmune

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.